Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Olema Pharmaceuticals stock
Own Olema Pharmaceuticals stock in just a few minutes.
Olema Pharmaceuticals, Inc is a biotechnology business based in the US. Olema Pharmaceuticals shares (OLMA) are listed on the NASDAQ and all prices are listed in US Dollars. Olema Pharmaceuticals employs 36 staff and has a market cap (total outstanding shares value) of USD0.00.
How to buy shares in Olema Pharmaceuticals
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Olema Pharmaceuticals. Find the stock by name or ticker symbol: OLMA. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Olema Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Olema Pharmaceuticals, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Olema Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Olema Pharmaceuticals share price
Use our graph to track the performance of OLMA stocks over time.Olema Pharmaceuticals shares at a glance
Information last updated 2021-04-15.
| 52-week range | USD$26.74 - USD$60.27 |
|---|---|
| 50-day moving average | USD$37.7387 |
| 200-day moving average | USD$43.1365 |
| Wall St. target price | USD$65 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | N/A |
Buy Olema Pharmaceuticals shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Olema Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Olema Pharmaceuticals financials
| Gross profit TTM | USD$0 |
|---|---|
| Return on assets TTM | -7.85% |
| Return on equity TTM | -13.13% |
| Profit margin | 0% |
| Book value | N/A |
| Market capitalisation | USD$1.4 billion |
TTM: trailing 12 months
Shorting Olema Pharmaceuticals shares
There are currently 860,988 Olema Pharmaceuticals shares held short by investors – that's known as Olema Pharmaceuticals's "short interest". This figure is 94.9% up from 441,853 last month.
There are a few different ways that this level of interest in shorting Olema Pharmaceuticals shares can be evaluated.
Olema Pharmaceuticals's "short interest ratio" (SIR)
Olema Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Olema Pharmaceuticals shares currently shorted divided by the average quantity of Olema Pharmaceuticals shares traded daily (recently around 257011.34328358). Olema Pharmaceuticals's SIR currently stands at 3.35. In other words for every 100,000 Olema Pharmaceuticals shares traded daily on the market, roughly 3350 shares are currently held short.
To gain some more context, you can compare Olema Pharmaceuticals's short interest ratio against those of similar companies.
- Puma Biotechnology (PBYI.US): 15.15
- Xenetic Biosciences (XBIO.US): 0.36
- Inovio Pharmaceuticals (INO.US): 5.93
- Oncorus (ONCR.US): 3.47
However Olema Pharmaceuticals's short interest can also be evaluated against the total number of Olema Pharmaceuticals shares, or, against the total number of tradable Olema Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Olema Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Olema Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0324% of the tradable shares (for every 100,000 tradable Olema Pharmaceuticals shares, roughly 32 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Olema Pharmaceuticals.
Find out more about how you can short Olema Pharmaceuticals stock.
Olema Pharmaceuticals share dividends
We're not expecting Olema Pharmaceuticals to pay a dividend over the next 12 months.
Olema Pharmaceuticals overview
Olema Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc.
Frequently asked questions
More guides on Finder
-
T. Rowe Price review
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
-
How to buy ZTO Express Cayman stock
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
-
How to buy Zomedica stock
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
-
How to buy ZoomInfo Technologies stock
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
-
How to buy ZK International Group CoLtd stock
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
-
How to buy Zions Bancorporation National Association stock
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
-
How to buy Zentalis Pharmaceuticals stock
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
-
How to buy Yunhong International stock
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
-
How to buy Zealand Pharma A/S stock
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
-
How to buy Yunhong CTI stock
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
Ask an Expert